Insmed jumps after forecasting preliminary 2025 revenue above estimates

Insmed

09/01/2026 14:27

** Shares of drugmaker Insmed INSM.O rise 11.6% to $190 premarket

** INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG

** Leerink Partners says Insmed blew consensus estimates out of the water "for the first full quarter of Brinsupri's launch, with sales of $144.6 million"

** Brinsupri was approved by U.S. FDA in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis

** Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million

** Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million

** "The actual results could be materially different from these preliminary unaudited financial results" - INSM

** "This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months," Leerink adds

** As of last close, stock has more than doubled in past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))